Last Monday, shares of Cleantech Solutions (CLNT) were trading as low as $3.42. By Thursday the shares had more than tripled to a high of $10.85. The stock, which normally trades around 60,000 shares per day, traded an astonishing 22 million shares over the course of last week. The timing of this surge was very…
Shares of Tesaro Inc (TSRO) have recently traded to new all time highs and are now sitting at $29.40 The shares have now more than doubled since coming public at $13.50 in June of 2012. However, a series of near term challenges to its lead drug candidate could see the shares drop back below $21.00…
Shares of TearLab (TEAR) have nearly doubled in 2013, buoyed by a stream of analyst upgrades from small, retail oriented brokerages. However, it now looks as if a near term equity offering will likely take the shares lower. Investment thesis Despite the recent bullish analyst reports, financial performance at TearLab has been consistently very poor….
Disclosure: I am short OPK. (More…) When I first raised the alarm about Ziopharm Oncology (ZIOP), I received death threats and threats of lawsuits from many retail investors. Some of these can still be found posted online. Many retail investors were so enthralled with this “guaranteed winner” that any suggestion to sell by anyone at any price was shouted down…
Investment Thesis ServiceNow insiders have now sold over $400 million of stock even after its IPO, disregarding bullish calls from research firms (who happen to also be its bankers). On February 1st – the first day of the February lockup expiration – the CEO and the company founder began selling large amounts…
Shares of Ziopharm Oncology (ZIOP) plunged by 64% to $1.82 on Tuesday when it released news that its only late stage drug candidate failed to meet its primary endpoint. For now, there isn’t much of a play except for those who may wish to bet on some further downside. No one can truly predict…
A bubble for tech stocks is clearly back. The NASDAQ has more than regained everything that was given up in the Great Recession and at 3,213 it has returned to levels not seen since the year 2000. Companies that provide technology solutions within the real estate industry are currently getting a very positive double…
Disclosure: I am short ALNY. The past 12-14 months have seen a very strong rally in the overall markets, sending the Nasdaq index to levels not seen in 13 years. Biotech stocks have largely been leading the pack and have provided spectacular returns to those who have been chasing the ultra-high beta returns. Since the beginning of 2012,…
Pacira Pharmaceuticals (PCRX) is an emerging specialty pharma company which in 2012 launched an opiate alternative (“Exparel”) for post surgical pain management. The product is currently approved for use in certain post surgical pain applications including removal of hemorrhoids and bunions. Since the product launch in April 2012, the shares have tripled, enjoying a boost…
Last week I published an article noting several sell signals which were emerging at Pacira Pharmaceuticals (PCRX), which was closing in on a triple since 2012. In just the past few weeks the shares have risen by more than 50%, to $30.00 from $20.00. Following my article, it was disclosed that MPM Asset Management, which employs both…
Shares of Opko Health (OPK) have risen 65% in the past three months as a string of domestic and international acquisitions, along with a greater collaboration with Bristol Meyers (BMY), has opened up numerous new pathways for the company. Opko’s prospects as a company continue to be bright, however at the current price of…
Shares of Unipixel have dropped 30% from their high in the last 2 weeks right as MDB capital pulled all of its research from the MDB website. Additional case studies of MDB deals had also been removed from MDB presentations. I have located archived copies which disclose the use of unregistered analysts who write the reports from Nicaragua as well as MDB’s right to go short the stock of companies it has promoted. MDB had taken large equity stakes (including free warrants) prior to publishing its bullish research.
Trina Solar has over $1.2 billion in total debt, with roughly $800 million coming due. Trina also has over $14 billion in off balance sheet liabilities which lock it in to purchasing its raw materials are prices which are well above market and for volumes which it can no longer support. The company has less than $600 million in cash and now selling its products below cost. However the share price has risen from by 125% in just 6 weeks to $4.92.
A factory explosion left Neptune Technologies (NEPT) with no factory, no revenues, no product and only 10 employees. Despite this, an aggressive promotion to retail investors by 3rd parties has suggested the share price should double to all time highs. In reality, the share price is more likely to fall by 50-70%.
Over the past few years, I have been a consistent bull on Baidu.com (BIDU), which has served me quite well on a number of occasions. However, as a number of new risks have emerged at the worst possible time, I am now turning very bearish on the share price going forward. Over the medium term…
Normally I try to shy away from very low priced stocks, however in the case of China BAK Battery (CBAK), it is a company which I have been quite familiar with for years while living in China. I am very well informed about the company’s complete insolvency as well as the unusual rise in its…
Cleantech Solutions (CLNT) is a tiny $12.0 million market cap company which describes its business as the manufacture of forged and fabricated products for end use primarily by manufacturers of windmills in China. The share price has nearly doubled in just the past week. The share price history of Cleantech is very confusing to some…
Following a 40% plunge in earnings last quarter and a drop of nearly 60% since last year, earnings at Hi-Tech Pharmacal (HITK) are once again set to plunge next week when earnings are released again. A stock drop of up to 60% appears to be approaching quickly. Ongoing fraud investigations have the potential to further exacerbate this drop in a meaningful way, but as a notably under-followed stock, Wall Street simply isn’t paying attention.
